Based on the results of this study, pembrolizumab is recommended in the 2020 NCCN guidelines for cervical cancer as a second-line regimen for recurrent cervical cancer indicated for PD-L1-positive or MSI-H/dMMR. Here, CD274 is linked to cervical cancer.